Immunogenicity and safety of routine 13-valent pneumococcal conjugate vaccination outside recommended age range in patients with hematological malignancies and solid tumors-Reference-Cited by-同舟云学术

Immunogenicity and safety of routine 13-valent pneumococcal conjugate vaccination outside recommended age range in patients with hematological malignancies and solid tumors

Published:2022-02 Issue:9 Volume:40 Page:1238-1245
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Takeshita Kenichi,Ishiwada Naruhiko,Takeuchi Noriko,Ohkusu Misako,Ohata Mihoko,Hino Moeko,Hishiki Haruka,Takeda Yusuke,Sakaida Emiko,Takahashi Yoshiko,Shimojo Naoki,Hamada Hiromichi

Funder

Japan Society for the Promotion of Science

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference33 articles.

1. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012;61:816–9.

2. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2013;62:521–4.

3. Current situation and need for prevention of invasive pneumococcal disease and pneumococcal pneumonia in 6- to 64-year-olds in Japan;Ishiwada;J Infect Chemother,2021

4. Invasive pneumococcal disease among immunocompromised persons: Implications for vaccination programs;Shigayeva;Clin Infect Dis,2016

5. Risk of pneumococcal diseases in adults with underlying medical conditions: A retrospective, cohort study using two Japanese healthcare databases;Imai;BMJ Open,2018

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mannan-Decorated Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Antitumor Immune Response by Modulating the Tumor Microenvironment;Journal of Functional Biomaterials;2024-08-16

2. Vaccination of Adults With Cancer: ASCO Guideline;Journal of Clinical Oncology;2024-05-10

3. Impact of Infection Patterns on the Outcomes of Patients with Hematological Malignancies in Southwest China: A 10-Year Retrospective Case-Control Study;Infection and Drug Resistance;2023-06

4. Side effects of vaccines;Side Effects of Drugs Annual;2023